Literature DB >> 22766659

Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome.

Juan Francisco Sánchez Muñoz-Torrero1, Dolores Rivas, Rodrigo Alonso, Leandro Crespo, Alberto Costo, Montaña Roman, Carlos Martín, José Zamorano.   

Abstract

OBJECTIVE: To examine the relation between plasma lipoprotein (a) (Lp[a]) levels and oxidative stress biomarkers, serum cytokines, and atherosclerotic burden among individuals recently diagnosed as having metabolic syndrome (MS).
METHODS: Eighty-four white patients with MS were classified according to two Lp(a) levels (normal Lp[a]: < 30 mg/dL or high Lp[a]: > 30 mg/dL) and were compared with 42 healthy controls. Oxidative stress biomarkers (oxidized low-density lipoprotein, antibodies to oxidized low-density lipoprotein, and nitric oxide metabolites) and proinflammatory cytokines (interleukin [IL]-2, IL-4, IL-5, IL-6, IL-10, IL-12P70, IL-13, and interferon-γ) were measured in plasma. Atherosclerotic significance was determined using carotid ultrasound and endothelial function by standardized protocols.
RESULTS: Patients with MS had higher levels of serum cytokines, oxidative stress markers, and C-reactive protein, and greater atherosclerosis burden as compared with controls. Among the group members, 58 patients had normal Lp(a) levels and 26 had high Lp(a) levels. Cytokines and C-reactive protein levels were significantly higher in patients with high Lp(a) compared with those with normal Lp(a) (P < 0.01 for IL-2 and P < 0.001 for the others). Nitric oxide metabolites were significantly lower in patients with high Lp(a) as compared with those with normal Lp(a) (P < 0.05). No differences were found in oxidized low-density lipoprotein and atherosclerotic burden between the two groups of patients with MS with respect to Lp(a) levels.
CONCLUSIONS: Elevated Lp(a) plasma levels are associated with higher proinflammatory markers in patients newly diagnosed as having MS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766659     DOI: 10.1097/SMJ.0b013e31825b5fb2

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

2.  Lipoprotein(a) and Metabolic Syndrome.

Authors:  Nikolaus Buchmann; Till Ittermann; Ilja Demuth; Marcello R P Markus; Henry Völzke; Marcus Dörr; Nele Friedrich; Markus M Lerch; Raul D Santos; Sabine Schipf; Elisabeth Steinhagen-Thiessen
Journal:  Dtsch Arztebl Int       Date:  2022-04-15       Impact factor: 8.251

3.  Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study.

Authors:  Valmore Bermúdez; Joselyn Rojas; Juan Salazar; Luis Bello; Roberto Añez; Alexandra Toledo; Maricarmen Chacín; Miguel Aguirre; Marjorie Villalobos; Mervin Chávez; María Sofía Martínez; Wheeler Torres; Yaquelin Torres; José Mejías; Edgardo Mengual; Liliana Rojas; Milagro Sánchez de Rosales; Ana Quevedo; Raquel Cano; Mayela Cabrera; Rafael París; Adonías Lubo; María Montiel; Climaco Cano
Journal:  J Diabetes Res       Date:  2013-04-22       Impact factor: 4.011

Review 4.  Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms.

Authors:  Paulo Ricardo Criado; Beatrice Martinez Zugaib Abdalla; Isabelle Carvalho de Assis; Cristina van Blarcum de Graaff Mello; Gabriela Cacciolari Caputo; Ingrid Campos Vieira
Journal:  Inflamm Res       Date:  2020-06-02       Impact factor: 6.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.